

Pardeep S Jhund

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9243476/pardeep-sjhund-publications-by-year.pdf>

Version: 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225 papers	12,084 citations	56 h-index	103 g-index
263 ext. papers	17,490 ext. citations	10.6 avg, IF	6.35 L-index

#	Paper	IF	Citations
225	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 104-118	7.9	0
224	Drug therapy for HFrEF: What is the "right" dose?. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	2
223	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022 , 10, 380-392	7.9	0
222	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 296-301	6.4	7
221	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
220	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
219	Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. <i>European Heart Journal</i> , 2021 ,	9.5	2
218	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2021 ,	16.7	1
217	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
216	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
215	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6.4	0
214	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008837	7.6	2
213	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021 , 44, 586-594	14.6	24
212	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. <i>Journal of Human Hypertension</i> , 2021 , 35, 1029-1037	2.6	0
211	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021 , 143, 516-525	16.7	85
210	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 617-628	12.3	14
209	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 601-613	12.3	14

208	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
207	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 254-264	7.9	23
206	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
205	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
204	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 499-507	16.2	35
203	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. <i>JAMA Cardiology</i> , 2021 , 6, 678-689	16.2	7
202	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 1130-1143	16.2	26
201	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1334-1349	6.1	1
200	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
199	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021 , 144, 199-209	16.7	14
198	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	16.7	69
197	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021 , 8, 129-138	3.7	6
196	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021 , 42, 1199-1202	9.5	18
195	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
194	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 632-643	12.3	8
193	Risk stratification in patients presenting with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 113-115	4.3	
192	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e019238	6	3
191	The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021 , 23, 1432-1436	12.3	0

190	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021 , 23, 1662-1672	12.3	6
189	Derivation and Validation of a 10-Year Risk Score for Symptomatic Abdominal Aortic Aneurysm: Cohort Study of Nearly 500 000 Individuals. <i>Circulation</i> , 2021 , 144, 604-614	16.7	0
188	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
187	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021 , 16, e0255364	3.7	0
186	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021 , 42, 3727-3738	9.5	22
185	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
184	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. <i>Kidney360</i> , 2021 , 2, 1761-1769	1.8	1
183	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
182	Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 1887-1896	2.3	1
181	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021 , 144, e40	16.7	2
180	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. <i>Circulation: Heart Failure</i> , 2020 , 13, e007879	7.6	7
179	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
178	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1247-1258	12.3	19
177	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	17.4	155
176	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1358-1365	5.1	5
175	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	9.5	80
174	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
173	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 811-818	7.9	44

172	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1495-1503	12.3	56
171	Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF". <i>Circulation</i> , 2020 , 142, e5-e6	16.7	5
170	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020 , 13, e006541	7.6	31
169	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020 , 22, 848-855	12.3	9
168	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 432-441	16.2	22
167	Dyslipidaemia, a factor worthy of adjustment: reply. <i>European Journal of Heart Failure</i> , 2020 , 22, 564-565	12.3	1
166	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2123-2133	12.3	22
165	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2356-2362	9.5	21
164	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 121-128	40	133
163	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 188-198	7.9	20
162	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. <i>Circulation</i> , 2020 , 141, 100-111	16.7	68
161	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , 2020 , 141, 90-99	16.7	130
160	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
159	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	12.3	16
158	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 196-213	12.3	85
157	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. <i>Diabetes Care</i> , 2020 , 43, 440-445	14.6	24
156	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020 , 8, 984-995	7.9	2
155	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1984-1986	12.3	44

154	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020 , 7, 3355	3.7	3
153	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	16.7	52
152	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2370-2379	12.3	9
151	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2147-2156 ^{12,3}	12.3	41
150	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020 , 43, 2878-2881	14.6	8
149	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	16.7	20
148	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e017462	6	15
147	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1236-1245	16.7	32
146	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2056-2064	12.3	14
145	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418 ^{9,5}	9.5	40
144	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	20
143	Healthcare disparities for women hospitalized with myocardial infarction and angina. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 156-165	4.6	7
142	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
141	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28
140	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
139	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 878-887	7.9	15
138	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 844-851	12.3	47
137	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. <i>Circulation</i> , 2019 , 140, 542-552	16.7	51

136	Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. <i>JACC: Heart Failure</i> , 2019 , 7, 457-465	7.9	54
135	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 418-427	7.9	10
134	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019 , 12, e005766	7.6	14
133	Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease. <i>Hypertension</i> , 2019 , 73, 1202-1209	8.5	36
132	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 336-346	7.9	42
131	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 868-877	6.1	9
130	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 776-785	18.1	522
129	Heart Failure with Reduced Ejection Fraction 2019 , 383-395		
128	Response by Welsh et al to Letter Regarding Article "Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease". <i>Hypertension</i> , 2019 , 74, e27-e28	8.5	1
127	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
126	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 974-984	12.3	30
125	Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. <i>Nature Medicine</i> , 2019 , 25, 1753-1760	50.5	68
124	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006539	7.6	36
123	Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control. <i>European Heart Journal Supplements</i> , 2019 , 21, M20-M24	1.5	
122	Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019 , 279, 126-132	3.2	2
121	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 29-40	15.1	86
120	Diabetic cardiomyopathy. <i>Heart</i> , 2019 , 105, 337-345	5.1	37
119	Contemporary Management of Heart Failure in the Elderly. <i>Drugs and Aging</i> , 2019 , 36, 137-146	4.7	7

118	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019 , 21, 577-587	12.3	22
117	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019 , 21, 40-49	12.3	31
116	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	12.3	65
115	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1139-1145	12.3	26
114	Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1415-1423	9.4	32
113	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018 , 41, 1285-1291	14.6	23
112	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	7.9	138
111	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
110	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018 , 20, 760-768	12.3	44
109	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1549-1556	12.3	11
108	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147	12.3	15
107	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018 , 20, 295-303	12.3	41
106	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018 , 138, 2774-2786	16.7	78
105	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. <i>Clinical Epidemiology</i> , 2018 , 10, 917-930	5.9	4
104	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. <i>European Heart Journal</i> , 2018 , 39, 3417-3438	9.5	29
103	Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. <i>European Heart Journal</i> , 2018 ,	9.5	2
102	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 41-48	7.9	1
101	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 514-522	12.3	20

100	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. <i>Heart</i> , 2018 , 104, 144-150	5.1	25
99	Peripartum cardiomyopathy: diagnosis and management. <i>Heart</i> , 2018 , 104, 779-786	5.1	9
98	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 240-247	12.3	12
97	Which patients with heart failure should receive specialist palliative care?. <i>European Journal of Heart Failure</i> , 2018 , 20, 1338-1347	12.3	38
96	Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2017 , 19, 1154-1163	12.3	101
95	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 919	15.1	4
94	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017 , 38, 1132-1143	9.5	109
93	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017 , 188, 35-41	4.9	24
92	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , 2017 , 135, 724-735	16.7	100
91	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 545-549	3.9	35
90	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
89	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017 , 38, 338-345	9.5	37
88	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017 , 38, 742-750	9.5	25
87	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 877-886	18.1	164
86	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1472-1477	3.8	17
85	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017 , 5, 591-599	7.9	10
84	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	34
83	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2490-2500	15.1	65

82	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	59.2	232
81	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 129-137	12.3	68
80	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation</i> , 2016 , 134, 1314-1324	16.7	79
79	Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study. <i>Circulation</i> , 2016 , 134, 999-1009	16.7	29
78	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	53
77	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016 , 18, 1162-71	12.3	21
76	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. <i>Heart</i> , 2016 , 102, 1342-7	5.1	91
75	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	201
74	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	68
73	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016 , 209, 310-6	3.2	19
72	Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. <i>European Heart Journal</i> , 2016 , 37, 1244-51	9.5	130
71	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016 , 37, 3167-3174	9.5	88
70	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1021-31	12.3	13
69	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. <i>European Heart Journal</i> , 2016 , 37, 3135-3140	9.5	18
68	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , 2016 , 133, 2254-62	16.7	96
67	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	7
66	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015 , 36, 939-45	9.5	62
65	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015 , 3, 603-14	7.9	26

64	Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. <i>European Journal of Heart Failure</i> , 2015 , 17, 196-204	12.3	12
63	Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8,	3.9	28
62	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 169-76	12.3	25
61	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015 , 17, 434-41	12.3	29
60	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , 2015 , 15, 3	3.1	6
59	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , 2015 , 131, 1481-91	16.7	66
58	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. <i>European Heart Journal</i> , 2015 , 36, 2463-9	9.5	25
57	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2059-2071	15.1	87
56	Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2092-2100	15.1	31
55	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , 2015 , 8, 717-24	7.6	15
54	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015 , 36, 2576-84	9.5	129
53	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials". <i>Circulation</i> , 2015 , 131, 1482-1483	16.7	1
52	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 478-486	7.9	17
51	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , 2015 , 131, 43-53	16.7	58
50	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015 , 36, 669-75	9.5	47
49	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015 , 17, 809-17	12.3	45
48	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. <i>Open Heart</i> , 2015 , 2, e000283	3	11
47	Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. <i>European Journal of Heart Failure</i> , 2015 , 17, 906-16	12.3	30

46	Diagnosis and resolution of Libffler endocarditis secondary to eosinophilic granulomatosis with polyangiitis demonstrated by cardiac magnetic resonance-T2 mapping. <i>Circulation</i> , 2015 , 131, 114-7	16.7	2
45	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	59.2	71
44	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	12.3	56
43	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014 , 16, 778-87	12.3	60
42	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014 , 35, 3426-33	9.5	10
41	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 289-97	7.9	84
40	Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 187-97	7.9	24
39	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014 , 35, 2714-21	9.5	50
38	Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014 , 7, 953-9	7.6	62
37	Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. <i>BMJ, The</i> , 2014 , 348, g1088	5.9	42
36	Low pulse pressure as a poor-man's indicator of a low cardiac index in patients with severe cardiac dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2014 , 15, 315-21	1.9	7
35	LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 561-9	8.4	20
34	Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). <i>JACC: Heart Failure</i> , 2014 , 2, 35-40	7.9	21
33	Effect of rosuvastatin on fatigue in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1121-2	15.1	6
32	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1845-54	15.1	62
31	Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. <i>International Journal of Cardiology</i> , 2013 , 167, 2149-55	3.2	15
30	Remodelling of human atrial K ⁺ currents but not ion channel expression by chronic β -blockade. <i>Pflugers Archiv European Journal of Physiology</i> , 2012 , 463, 537-48	4.6	14
29	What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2349-56	15.1	136

28	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2012 , 33, 314-24	9.5	72
27	Reply to the letter by Dr Erqou regarding Intensive glycemc control has no impact on the risk of heart failure in type 2 diabetic patients□ <i>American Heart Journal</i> , 2012 , 163, e37	4.9	
26	How small is too small? A systematic review of center volume and outcome after cardiac transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 783-90	5.8	31
25	Heart failure and socioeconomic status: accumulating evidence of inequality. <i>European Journal of Heart Failure</i> , 2012 , 14, 138-46	12.3	164
24	Prior psychiatric hospitalization is associated with excess mortality in patients hospitalized with non-cardiac chest pain: a data linkage study based on the full Scottish population (1991-2006). <i>European Heart Journal</i> , 2012 , 33, 760-7	9.5	4
23	Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2127-38	15.1	104
22	Intensive glycemc control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. <i>American Heart Journal</i> , 2011 , 162, 938-948.e2	4.9	116
21	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011 , 11, 38	3.1	15
20	Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. <i>Diabetes Care</i> , 2010 , 33, 1213-8	14.6	106
19	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1301-5	5.5	34
18	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010 , 12, 17-24	12.3	65
17	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 607-16	12.3	50
16	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010 , 8, 23	11.4	24
15	Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 475-83	5.8	19
14	Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009 , 40, 1038-43	6.7	60
13	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 130-9	12.3	324
12	Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. <i>Circulation</i> , 2009 , 119, 515-23	16.7	393
11	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. <i>European Journal of Heart Failure</i> , 2009 , 11, 632-633	12.3	

10	Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. <i>Circulation: Heart Failure</i> , 2008 , 1, 234-41	7.6	51
9	Heart failure after acute myocardial infarction: a lost battle in the war on heart failure?. <i>Circulation</i> , 2008 , 118, 2019-21	16.7	81
8	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. <i>Heart</i> , 2007 , 93, 606-12	5.1	119
7	Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: an analysis of the Renfrew/Paisley Study. <i>European Journal of Heart Failure</i> , 2006 , 8, 856-63	12.3	32
6	Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. <i>Circulation</i> , 2006 , 113, 2566-8	16.7	6
5	Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 2005 , 19, 261-5	3.9	11
4	17 α oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenopausal women. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 31-6	3.9	2
3	Attenuation of endothelin-1 induced vasoconstriction by 17 β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1367-73	15.1	19
2	Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1234-8	15.1	22
1	The acute vascular effects of frusemide in heart failure. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 9-13	3.8	25